daclizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4953 152923-56-3

Description:

MoleculeDescription

Synonyms:

  • zinbryta
  • daclizumab
  • zenapax
An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
5 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 26, 1999 EMA
Dec. 10, 1997 FDA HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2367.98 49.14 405 4454 4279 50595986
Transplant rejection 1899.59 49.14 376 4483 9233 50591032
Ovarian cyst 1690.22 49.14 364 4495 13632 50586633
Acne 1584.27 49.14 367 4492 19228 50581037
Alopecia 824.77 49.14 418 4441 244629 50355636
Sleep disorder due to general medical condition, insomnia type 417.61 49.14 144 4715 31303 50568962
Liver function test abnormal 394.36 49.14 151 4708 44188 50556077
Multiple sclerosis relapse 259.77 49.14 111 4748 42853 50557412
Rheumatoid arthritis 183.90 49.14 153 4706 202397 50397868
Pneumonia 138.46 49.14 175 4684 378226 50222039
Condition aggravated 134.14 49.14 153 4706 296905 50303360
Loss of personal independence in daily activities 120.41 49.14 78 4781 69972 50530293
Incorrect route of product administration 95.61 49.14 43 4816 18623 50581642
Overdose 91.47 49.14 76 4783 99651 50500614
Kidney transplant rejection 84.13 49.14 26 4833 3961 50596304
Pain 79.30 49.14 172 4687 578731 50021534
Product use issue 67.11 49.14 77 4782 149398 50450867

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 149.72 36.32 36 521 11383 29562587

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2330.09 49.09 408 4579 6300 64487445
Ovarian cyst 1861.45 49.09 365 4622 10653 64483092
Transplant rejection 1740.63 49.09 373 4614 17028 64476717
Acne 1603.20 49.09 367 4620 22714 64471031
Alopecia 1061.45 49.09 416 4571 165274 64328471
Sleep disorder due to general medical condition, insomnia type 473.69 49.09 144 4843 26126 64467619
Liver function test abnormal 386.70 49.09 152 4835 59249 64434496
Multiple sclerosis relapse 298.45 49.09 114 4873 41021 64452724
Rheumatoid arthritis 239.94 49.09 152 4835 164142 64329603
Condition aggravated 138.02 49.09 156 4831 372270 64121475
Loss of personal independence in daily activities 133.55 49.09 78 4909 72376 64421369
Pneumonia 118.89 49.09 178 4809 559398 63934347
Pain 106.14 49.09 168 4819 553343 63940402
Incorrect route of product administration 95.40 49.09 43 4944 23255 64470490
Product use issue 85.79 49.09 80 4907 151635 64342110
Overdose 82.35 49.09 80 4907 159486 64334259
Drug ineffective 64.61 49.09 175 4812 840072 63653673
Encephalitis autoimmune 50.08 49.09 14 4973 1870 64491875

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA MoA N0000010279 Interleukin 2 Receptor Antagonists
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
FDA MoA N0000175621 Interleukin 2 Receptor-directed Antibody Interactions
FDA EPC N0000175622 Interleukin-2 Receptor Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal transplant rejection indication 236570004
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-2 receptor Membrane receptor ANTIBODY BINDING Kd 8 IUPHAR DRUG LABEL

External reference:

IDSource
D03639 KEGG_DRUG
4021083 VUID
N0000148541 NUI
4021083 VANDF
CHEMBL1201605 ChEMBL_ID
6880 IUPHAR_LIGAND_ID
7164 INN_ID
DB00111 DRUGBANK_ID
CUJ2MVI71Y UNII
1795335 RXNORM
11508 MMSL
241453 MMSL
4529 MMSL
d04262 MMSL
109133001 SNOMEDCT_US
386977009 SNOMEDCT_US
D000077561 MESH_DESCRIPTOR_UI
C0663182 UMLSCUI
007284 NDDF

Pharmaceutical products:

None